The antifibrotic potential of a sustained release formulation of a PDGF beta-receptor targeted rho kinase inhibitor

F. van Dijk, N. Teekamp, E. Post, D. Schuppan, Y. O. Kim, J. Zuidema, R. Steendam, Matthias H. M. Klose, Samuel M. Meier-Menches, A. Casini, P. L. Horvatovich, N. J. Sijbrandi, H. W. Frijlink, W. L. J. Hinrichs, K. Poelstra, L. Beljaars, P. Olinga*

*Corresponding author voor dit werk

OnderzoeksoutputAcademicpeer review

18 Citaten (Scopus)
371 Downloads (Pure)


Rho kinase activity in hepatic stellate cells (HSCs) is associated with activation, transformation and contraction of these cells, leading to extracellular matrix production and portal hypertension in liver cirrhosis. Inhibition of rho kinase activity can reduce these activities, but may also lead to side effects, for instance systemic hypotension. This can be circumvented by liver-specific delivery of a rho kinase inhibitor to effector cells. Therefore, we targeted the rho kinase inhibitor Y27632 to the key pathogenic cells in liver fibrosis, i.e. myofibroblasts including activated HSCs that highly express the PDGF beta-receptor, using the drug carrier pPB-MSA. This carrier consists of mouse serum albumin (MSA) covalently coupled to several PDGF beta-recognizing moieties (pPB). We aimed to create a prolonged release system of such a targeted construct, by encapsulating pPB-MSA-Y27632 in biodegradable polymeric microspheres, thereby reducing short-lasting peak concentrations and the need for frequent administrations. Firstly, we confirmed the vasodilating potency of PDGF beta-receptor targeted Y27632 in vitro in a contraction assay using HSCs seeded on a collagen gel. We subsequently demonstrated the in vivo antifibrotic efficacy of pPB-MSA-Y27632-loaded microspheres in the Mdr2 - / - mouse model of progressive biliary liver fibrosis. A single subcutaneous microsphere administration followed by organ harvest one week later clearly attenuated liver fibrosis progression and significantly suppressed the expression of fibrosis related genes, such as several collagens, profibrotic cytokines and matrix metalloproteinases. In conclusion, we demonstrate that polymeric microspheres are suitable as drug delivery system for the sustained systemic delivery of targeted protein constructs with antifibrotic potential, such as pPB-MSA-Y27632. This formulation appears suitable for the sustained treatment of liver fibrosis and possibly other chronic diseases.

Originele taal-2English
Pagina's (van-tot)250-257
Aantal pagina's8
TijdschriftJournal of Controlled Release
Vroegere onlinedatum22-jan.-2019
StatusPublished - 28-feb.-2019


Duik in de onderzoeksthema's van 'The antifibrotic potential of a sustained release formulation of a PDGF beta-receptor targeted rho kinase inhibitor'. Samen vormen ze een unieke vingerafdruk.

Citeer dit